Plexus' weak revenue outlook will weigh on the company s 2011 results. Intense competition in the EMS market, small market share, continued component challenges and supply chain constraints pose threats.
We remain apprehensive about the company meeting its 2011 targets and expect revenues to be down with difficult operating performance. We have reduced our estimates for fiscal 2011 and downgrade the stock to Underperform. We lower our target price to $25.00.
PLEXUS CORP (PLXS): Free Stock Analysis Report
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.